zffoto / Shutterstock.com
A US advisory panel has reportedly approved the use of the CRISPR/Cas9 gene-editing technology on humans for the first time, as part of a study designed to target three types of cancer.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CRISPR, cancer, US advisory panel, FDA, human trial
